Accredo
Therapeutics is a national network of pharmacies providing
nursing and pharmacy services, as well as all four FDA-approved
therapies to patients with Pulmonary Arterial Hypertension.
Actelion
A subsidiary of a Swiss drug development company by the same name,
which focuses on the endothelin. They are the developer of bosentan
(Tracleer®), an oral dual endothelin receptor antagonist. Actelion has
also in-licensed Ventavis® (iloprost) Inhalation Solution, from
Schering AG, for the treatment of pulmonary arterial hypertension, an
orphan indication, for the U.S. market.
Biogen Idec
(the result of a 2003 merger between Biogen, Inc and IDEC
Pharmaceuticals Corporation) is developing Aviptadil (vasoactive
intestinal polypeptide) in collaboration with mondoBIOTECH. This
inhalable medication is currently in Phase III clinical trials.
Caremark program offers support with the nursing care, pharmacy, distribution,
and reimbursement for Flolan®, Tracleer®, and Remodulin®.
Theracom site:Offers
comprehensive reimbursement, clinical, and data collection and
reporting solutions customized for the biotechnology and pharmaceutical
manufacturer.
Curascript Therapeutics One of the providers of Remodulin®
and Ventavis®. This company is a national distributor of
specialty pharmaceuticals and related medical supplies to the
alternate healthcare market.
Eli Lillyis the developer of Cialis (tadalafil). This oral medication is currently in Phase III trials for the treatment of PAH.
Encysive Pharmaceuticals
is a biopharmaceutical company and the developers of sitaxsentan
(Thelin®), which currently remains in Phase III clinical trials.
Sitaxsentan is a small molecule that antagonizes the action of
endothelin, a potent mediator of blood vessel constriction and growth
of smooth muscle in vascular walls.
Gilead Sciences,
formerly Myogen, is the maker of Letairis (ambrisentan). Gilead
develops pharmaceuticals for a variety of life-threatening illnesses,
including cardiovascular diseases. Gilead also markets and distributes
Flolan through an agreement with GlaxoSmithKline.
Lung Rxis
a separately managed affiliate of United Therapeutics focusing on
several pharmaceutical products, including one early stage gene therapy
solution for pulmonary hypertension (autologous cell-mediated eNOS).
Pfizer
is the developer of Revatio® (sildenafil citrate), an oral PAH treatment approved by the FDA in June 2005.
Helpingpatients.org
is their website dedicated to assisting patients and physicians
determine eleigibility for available pharmaceutical support
programs.
United
Therapeutics A niche pharmaceutical/disease management company
dedicated to the development and marketing of innovative therapies
for serious lung diseases, with a strong focus on PH.
PEER Network
(Patients Exchanging Experiences with Remodulin) The goal of PEER is to
provide an opportunity for people who are considering or who have
recently started Remodulin to talk with an experienced Remodulin
patient, called a PEER Mentor.
Other Companies Working in the Field:
Fairview Specialty Pharmacy
provides personal medication management services for commonly
prescribed pulmonary hypertension therapies including Letairis
(Ambrisentan) and Revatio.
Medtronic
manufactures pumps for use with Remodulin. Also manufactures
a host of other products and therapies.
Pharmacare
provides specialty pharmacy services for Tracleer.
Respironics provides information on sleep and respiratory issues.
Smiths Medical manufactures pumps for use with Flolan. Also manufactures a
host of other products and therapies.
[an error occurred while processing this directive]
[an error occurred while processing this directive]